Recent Development of Hydrogen Sulfide Therapeutics in the Treatment of Cardiovascular Diseases

Title:Recent Development of Hydrogen Sulfide Therapeutics in the Treatment of Cardiovascular Diseases

Volume: 21 Issue: 24

Author(s): Wen Peng, Weiwei Guo*Yueqing Zheng*

Affiliation:

• Academic Institute of Pharmaceutical Science China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing, 210009,China

• Academic Institute of Pharmaceutical Science China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing, 210009,China

Keywords: Hydrogen sulfide (H₂S), Gasotransmitter, Cardiovascular diseases (CVDs), H2S prodrug, Thrombosis, Astrocytes.

Abstract: Hydrogen sulfide (H₂S), as one of the endogenous gasotransmitters, has shown great potential in treating cardiovascular diseases (CVDs). H₂S plays a protective role in CVDs by removing reactive oxygen species (ROS), promoting vasodilation, inhibiting myocardial hypertrophy, preventing thrombosis, and protecting mitochondria. However, there still exist some problems for H₂S as drugs such as challenging delivery, uncontrollable release rate, and other drug developability issues. Addressing these problems, the prodrug strategy shows great potential. Therefore, a key issue on the H₂S-based therapeutics is developing appropriate H2S prodrugs. In this review, we mainly discussed the mechanism of H₂S against CVDs and reviewed the cardiovascular effects of current H₂S prodrugs.

Cite this article as:

Peng Wen , Guo Weiwei *, Zheng Yueqing*, Recent Development of Hydrogen Sulfide Therapeutics in the Treatment of Cardiovascular Diseases, Current Topics in Medicinal Chemistry 2021; 21 (24) . https://dx.doi.org/10.2174/1568026621666210831163817